Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, NYU Add Neonatal Heart Disorder to miRNA Cancer Alliance

NEW YORK (GenomeWeb News) — Rosetta Genomics has added congenital neonatal cardiovascular disease to a collaboration with the New York University School of Medicine that was originally created to use miRNA technology to develop cancer diagnostics, the company said today.
  
Rehovot, Israel-based Rosetta Genomics said the research will screen for specific miRNA biomarkers and signatures that could help diagnose or target congenital heart disease in newborns.
 
Around 40,000, or one out of every 125, US infants are born with CHD, which is caused by the improper development of vessels near the heart, the company said.
 
"It is now clear that microRNAs play a key role in controlling diverse aspects of cardiac development and response to disease," David Meyer, director of the Pediatric and Congenital Cardiothoracic Surgery at NYU, said in a statement.
 
“Recent studies have revealed key roles of microRNAs as regulators of growth, development, function, and responses to stress in the heart,” Rosetta Genomics said, adding that these “regulatory mechanisms may serve as potential diagnostic biomarkers and therapeutic targets for the treatment of heart disease.”
 
Financial terms of the expanded agreement were not released.
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more